Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  General Electric Company    GE

GENERAL ELECTRIC COMPANY

(GE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

General Electric : GE Healthcare Receives FDA Clearance of the Industry's First Contrast-Enhanced Mammography Solution for Biopsy

share with twitter share with LinkedIn share with facebook
06/10/2020 | 05:37am EDT

Chicago, Illinois -- To help empower clinicians and patients in their fight against breast cancer, GE Healthcare today announced the Food and Drug Administration's 510(k) clearance of Pristina Serena Bright(TM)*, the healthcare industry's first contrast-enhanced mammography solution for biopsy.

The clearance comes at a time when women's health clinics worldwide begin to reopen and are managing new protocols to help reduce staff and patient exposure to COVID-19. In the United States alone, breast cancer screenings experienced more than a 90% decline due to the pandemic.[1]

Accordingly, the Society of Breast Imaging has recommended providers consider the use of abbreviated breast procedures to reduce the time a patient is in the clinic and reduce staff to only essential employees.[2]

With Pristina Serena Bright, breast biopsy exams can now be done with the same mammography equipment, with the same staff, and in the same room as the screening or diagnostic mammogram. Previously, for lesions not seen on mammography or ultrasound, contrast-enhanced biopsy was typically performed with breast MRI. When compared to MRI-biopsy guided therapy, the potential benefits of Contrast Enhanced Spectral Mammography (CESM) biopsy include shortened procedure time, improved patient comfort, and reduced cost for patients.

"The waiting list for MRI-guided biopsy can be as long as several weeks. With CESM guided biopsies, we can schedule patients in less than one week after their initial CESM," said Dr. Rodrigo Alcantara, Head of Breast Imaging Section at Hospital del Mar in Spain. "This new mammography-guided biopsy techniques allows for a comfortable experience and provides women with answers quickly."

Key to this technology's application is GE Healthcare's SenoBright(TM) HD CESM, which allows clinicians to perform an entire breast exam in typically less than seven minutes with the images available immediately for a radiologist to review.[3] By highlighting areas of unusual blood flow to help localize lesions that need to be biopsied, CESM biopsy - Serena Bright(TM) - can help improve radiologists' diagnostic confidence.

"Now more than ever, it is critical we put the comfort of patients first and get them answers as fast as possible. We are proud to announce this FDA clearance during a time our customers need this type of innovation the most," said Agnes Berzsenyi, President and CEO of Women's Health at GE Healthcare. "We look forward to bringing this technology to the market in the upcoming months and hope it can help improve breast cancer outcomes for women during this time of uncertainty."

*Not yet commercially available.

###

About GE Healthcare:

GE Healthcare is the $16.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

Media Contact:

Kate Rodgers

Katlynn.rodgers@ge.com

+1 617-872-1214

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
Latest news on GENERAL ELECTRIC COMPANY
08/10BRAIN GAIN : Stunning new MRI tech advances neuro research and clinical translat..
PU
08/06Trump to Sign Executive Order to Boost U.S. Production of Essential Medicine ..
DJ
08/05GENERAL ELECTRIC : GE Research Uses Summit Supercomputer for Groundbreaking Stud..
PU
08/04GENERAL ELECTRIC : Thinking about trading options or stock in Beyond Meat, Qualc..
PR
08/04GENERAL ELECTRIC : GE Unveils Inkjet-Printed Red Phosphor (PFS-KSF) with Eyes on..
PU
08/04GENERAL ELECTRIC : GE Renewable Energy Signs Agreement with Walcha Energy to Acc..
PU
08/03Nordex shares hit five-month high on $474 million project pipeline sale
RE
08/03GENERAL ELECTRIC : GE Renewable Energy selected to supply Cypress wind turbines ..
PU
08/03The World Has Too Many Jet Engines -- Heard on the Street
DJ
08/01DAVID COTE : David Cote -- WSJ
DJ
More news
Financials (USD)
Sales 2020 78 711 M - -
Net income 2020 4 238 M - -
Net Debt 2020 17 327 M - -
P/E ratio 2020 14,6x
Yield 2020 0,60%
Capitalization 58 384 M 58 384 M -
EV / Sales 2020 0,96x
EV / Sales 2021 0,93x
Nbr of Employees 205 000
Free-Float 74,4%
Chart GENERAL ELECTRIC COMPANY
Duration : Period :
General Electric Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENERAL ELECTRIC COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 8,21 $
Last Close Price 6,67 $
Spread / Highest target 64,9%
Spread / Average Target 23,2%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
H. Lawrence Culp Chairman & Chief Executive Officer
Carolina Dybeck-Happe Chief Financial Officer & Senior Vice President
Victor Abate Chief Technology Officer & Senior Vice President
James S. Tisch Independent Director
Francisco D'Souza Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENERAL ELECTRIC COMPANY-40.23%58 384
HONEYWELL INTERNATIONAL INC.-9.93%111 885
SIEMENS AG-0.69%108 177
3M COMPANY-8.49%92 993
ILLINOIS TOOL WORKS INC.9.02%61 914
HITACHI, LTD.-28.23%30 341